Ambry Genetics / Tempus AI
Class Action Lawsuit
Posted: April 2, 2026 -- Ambry Genetics / Tempus AI genetic privacy class action lawsuit investigation.
Abington Cole + Ellery is investigating allegations that Tempus AI improperly compelled Ambry Genetics to disclose patients’ genetic testing results and related information without obtaining the written consent required by various genetic information privacy statutes.
FREE CONSULTATION: If you previously used Ambry Genetics' testing services and are interested in potentially volunteering to serve as a class representative in a class action lawsuit against Tempus AI, please submit your information here to be considered:
An attorney-client relationship is not formed by submitting information through this website.
What happened with Ambry Genetics and Tempus AI?
Tempus AI, a Chicago-based healthcare technology company focused on AI-driven precision medicine and genomic data, acquired Ambry Genetics (a clinical genetic testing lab specializing in hereditary cancer and rare disease testing) in a deal announced in late 2024 and closed on February 3, 2025, for approximately $600 million ($375 million cash + $225 million in shares).
Ambry had conducted genetic testing on over 2.5 million patients and maintained a large database of genetic information (including through its AmbryShare program). Tempus sought the acquisition to expand its germline testing capabilities, incorporate Ambry’s data into its AI algorithms and multimodal datasets, and create a continual feed of new genetic data for research, clinical use, and licensing to third parties (e.g., pharmaceutical companies).
What is the Tempus AI lawsuit about?
Lawsuits claim that Tempus AI improperly compelled Ambry Genetics to disclose patients’ genetic testing results and related information without obtaining the written consent required by genetic information privacy statutes. Genetic information privacy statutes treat genetic information as confidential and privileged; generally prohibiting disclosure or compelled release except to the tested individual or those they specifically authorize in writing. The suits further allege that, after the acquisition, Tempus disclosed (or licensed) this data to numerous third parties—including major pharma companies such as AstraZeneca, Pfizer, Merck, and others—without patient knowledge or consent, often to train AI models, support research, or for data licensing agreements (e.g., a $200 million deal with AstraZeneca).
Plaintiffs argue that even if Tempus claims the data was “de-identified,” the protections afforded by various genetic information privacy statutes still apply, and genetic data is uniquely identifiable (DNA is inherently personal and can potentially be re-identified). They point to Tempus’s own descriptions of its services, which enable detailed patient journey analysis, as evidence that full de-identification may not have occurred.
Additional Information:
(Article) Tempus AI Sued For Breach of Genetic Information Privacy Act
(Lawsuit) Nash v. Tempus AI, Inc. (Case No. 1:26-cv-01688, filed February 13, 2026
If you would like to volunteer to serve as a class representative in a class action lawsuit , please submit your information via the form on this webpage. This website is not associated with nor authorized by Tempus AI or Ambry Genetics or any affiliated companies.